Evaluate report signals orphan drug market is niche no more

London, UK – 28 April 2022 – Evaluate, the leading provider of market intelligence and predictive analytics for the pharmaceutical industry, has today released the findings of its 2022 Orphan Drug Report.

Evaluate’s data shows that the orphan drug market is growing more than twice as fast as the non-orphan pharmaceuticals market, with 2021-2026 CAGR topping 12%. By 2026 orphan drug sales will account for 20% of all prescription drug sales and almost a third of the global drug pipeline’s value. Each of the top ten orphan blockbusters in 2026 will be worth between $3 billion and $13 billion and look set to out-size mass market drugs.

Big pharma’s increasing reliance on orphan drugs for sales is anticipated to continue, with nine of the top-ten best-selling orphan drugs in 2026 expected to be marketed or co-marketed by big pharma. Over a fifth of sales at eight big pharma will also be from orphans. Four blood cancer drugs will account for about half of the $65 billion combined sales from 2026’s top ten orphans.

Paul Verdin, VP Consulting and Analytics at Evaluate said: “The orphan drug sector continues to experience rapid growth. Over half of the FDA’s approvals in 2021 were assigned to orphan drugs intended to treat rare diseases, a development that signals that orphan drugs should no longer be regarded as niche products.

“Orphans’ strong growth is leading to crowding in some corners of the market, but many of the estimated 7,000 rare diseases remain under-served, so the opportunity for further investment and R&D is high. As other diseases are better understood and sliced into narrower sub-categories, they are more likely to meet the criteria for a rare condition,” he added.

The report notes that the rise of orphan drug blockbusters may drive calls to reform the 40 year old US Orphan Drug Act and the European Union’s 1999 Orphan Regulation to temper prices. While this may result in changes to reimbursement, especially in Europe’s biggest market, Germany, the orphan drug market shows no sign of losing momentum.

The pharma R&D pipeline is currently packed with next-generation CAR-T cell therapies, gene therapies, targeted cancer drugs and other new modalities – many with orphan designations. The net present value of forecast 2026 sales of the top ten pipeline orphan drugs is more than $42 billion.

Read the 2022 Evaluate Orphan Drug Report in full here: https://www.evaluate.com/thought-leadership/pharma/orphan-drug-2022-report?utm_source=PR&utm_medium=PR&utm_campaign=Orphan_Drug_2022


Lisa Baker is the Editor of International Business News. As the Owner of Need to See IT Publishing, Lisa is an experienced business and technology journalist and publisher.

News Recruitment Tech Talent

hackajob launches in the U.S as demand for tech talent soars

Market leading tech recruitment platform hackajob launches in the U.S as tech employment set to reach 8.9 million in 2022[1] U.S launch comes as the rise of remote working sees 67% of tech talent widen their job search beyond their locality Leading UK-based tech recruitment platform hackajob launches today in the U.S. hackajob’s goal to […]

Read More
Data & Analytics News Tech

Why data is key in turning passion into profit for the creator economy

Written by Paul Scholey, VP of International Sales, Sisense In this article, Paul Scholey, a leading expert from Sisense, and Nicolette Roses-Agoro, Disciple’s Head of Community and Brand, discuss how data and analytics are not just shaping but powering the future of the flourishing creator economy. The creator economy is defined as a new community […]

Read More
Cybersecurity News

ThreatQuotient Selected By Comcast To Support Cybersecurity Operations

ThreatQ Platform and ThreatQ Investigations will be used by telecom conglomerate Comcast, parent of NBC Universal and SKY Group, to operationalise security intelligence across cybersecurity use cases London, UK. – May 17, 2022 – ThreatQuotient™, a leading security operations platform innovator, today announced that Comcast (NASDAQ:CMCSA) has selected the ThreatQ Platform and ThreatQ Investigations to […]

Read More